Pfizer Launches New Treatment For Overactive Bladder

Published: 02-Jun-2009

Toviaz, a once daily prescription drug, is available in doses of 4mg and 8mg

Pfizer has announced the launch of Toviaz (fesoterodine fumarate), an extended release tablets and YourWay plan, a customizable support plan for overactive bladder patients, which are now available in the US.

Toviaz is a once daily prescription drug for patients with symptoms of overactive bladder, which include frequent and sudden urges to urinate and wetting accidents. Toviaz works by helping to calm the bladder muscle that causes frequent, sudden urges to urinate.

Toviaz is available in two efficacious doses, 4mg and 8mg, allowing dosing flexibility to optimize treatment based on the individual patient response and tolerability.

The YourWay plan is a free, simple 12 week program designed to help physicians educate patients about their condition and treatment expectations, and to encourage and empower patients to become more engaged in their treatment, said the company.

Olivier Brandicourt, President and General Manager of Primary Care Business Unit at Pfizer, said: “Pfizer is proud to introduce Toviaz, which offers the flexibility of two efficacious doses to treat patients based on individual need, plus the innovative YourWay program.”

Tell your friend about this article